Login / Signup

Azacitidine effectively reduces TP53-mutant leukemic cell burden in secondary acute myeloid leukemia after cord blood transplantation.

Tomomi TakeiKazuaki YokoyamaEigo ShimizuTakaaki KonumaSatoshi TakahashiRui YamaguchiSeiya ImotoSatoru MiyanoArinobu Tojo
Published in: Leukemia & lymphoma (2018)
Keyphrases
  • acute myeloid leukemia
  • cord blood
  • cell therapy
  • allogeneic hematopoietic stem cell transplantation
  • single cell
  • risk factors
  • stem cells
  • bone marrow